Literature DB >> 17552873

Overweight and decreased baroreflex sensitivity as independent risk factors for hypertension in children, adolescents, and young adults.

K Krontorádová1, N Honzíková, B Fiser, Z Nováková, E Závodná, H Hrstková, P Honzík.   

Abstract

We studied the relationship between blood pressure (BP), body mass index (BMI, kg/m(2)) and baroreflex sensitivity (BRS, ms/mmHg) in adolescents. We examined 34 subjects aged 16.2+/-2.4 years who had repeatedly high causal BP (H) and 52 controls (C) aged 16.4+/-2.2 years. Forty-four C and 22 H were of normal weight (BMI between 19-23.9), and 8 C and 12 H were overweight (BMI between 24-30). Systolic BP was recorded beat-to-beat for 5 min (Finapres, controlled breathing 0.33 Hz). BRS was determined by the cross-spectral method. The predicting power of BMI and BRS for hypertension was evaluated by sensitivity, specificity, and receiver operating curve (ROC - plot of sensitivity versus specificity). H compared with C had lower BRS (p<0.01) and higher BMI (p<0.05). Multiple logistic regression analysis (p<0.001) revealed that a decreased BRS (p<0.05) and an increased BMI (p<0.01) were independently associated with an increased risk of hypertension. No correlation between BMI and BRS was found either in H or in C. Following optimal critical values by ROC, the sensitivity, specificity and area under ROC were determined for: BMI - 22.2 kg/m(2), 61.8 %, 69.2 %, 66.0 %; BRS - 7.1 ms/mmHg, 67.7 %, 69.2 %, 70.0 %; BMI and BRS - 0.439 a.u., 73.5 %, 82.7 %, and 77.3 %. Decreased BRS and overweight were found to be independent risk factors for hypertension.

Entities:  

Mesh:

Year:  2007        PMID: 17552873     DOI: 10.33549/physiolres.931250

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  7 in total

1.  Effect of Low Dose Atorvastatin Therapy on Baroreflex Sensitivity in Hypertensives.

Authors:  Denisa Celovska; Peter Kruzliak; Luis Rodrigo; Jozef Gonsorcik; Peter Sabaka; Peter Gaspar; Delian Delev; Daniel Petrovic; Andrej Dukat; Ludovit Gaspar
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-05-09

2.  Baroreflex gain in children with obstructive sleep apnea.

Authors:  Keith McConnell; Virend K Somers; Thomas Kimball; Stephen Daniels; Rhonda VanDyke; Matthew Fenchel; Aliza Cohen; Paul Willging; Abu Shamsuzzaman; Raouf Amin
Journal:  Am J Respir Crit Care Med       Date:  2009-03-12       Impact factor: 21.405

3.  Negative association between lipoprotein associated phospholipase A2 activity and baroreflex sensitivity in subjects with high normal blood pressure and a positive family history of hypertension.

Authors:  D Čelovská; K Vlčková; J Gonsorčík
Journal:  Physiol Res       Date:  2021-03-08       Impact factor: 1.881

4.  Monosodium glutamate neonatal treatment induces cardiovascular autonomic function changes in rodents.

Authors:  Signorá Peres Konrad; Vera Farah; Bruno Rodrigues; Rogério Brandão Wichi; Ubiratan Fabres Machado; Heno Ferreira Lopes; Beatriz D'Agord Schaan; Kátia De Angelis; Maria Cláudia Irigoyen
Journal:  Clinics (Sao Paulo)       Date:  2012-10       Impact factor: 2.365

5.  The analysis of a reference value for baroreflex sensitivity and cardiovascular autonomic neuropathy prevalence in a Chinese population.

Authors:  Zi-Hui Tang; Fangfang Zeng; Kuangping Ye; Xiaoling Yu; Linuo Zhou
Journal:  Eur J Med Res       Date:  2014-02-12       Impact factor: 2.175

6.  Cardiac Autonomic Adjustments During Baroreflex Test in Obese and Non-Obese Preadolescents.

Authors:  Mário Augusto Paschoal; Aline Carnio Brunelli; Gabriela Midori Tamaki; Sofia Serafim Magela
Journal:  Arq Bras Cardiol       Date:  2016-03-22       Impact factor: 2.000

7.  Comparison of Baroreflex Sensitivity and Cardiac Autonomic Function Between Adolescent Athlete and Non-athlete Boys - A Cross-Sectional Study.

Authors:  Senthil Kumar Subramanian; Vivek Kumar Sharma; Vinayathan Arunachalam; Rajathi Rajendran; Archana Gaur
Journal:  Front Physiol       Date:  2019-08-22       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.